BR112021020426A2 - Anticorpos anti-cd3 dependentes de ph projetados e métodos para sua geração e uso - Google Patents

Anticorpos anti-cd3 dependentes de ph projetados e métodos para sua geração e uso

Info

Publication number
BR112021020426A2
BR112021020426A2 BR112021020426A BR112021020426A BR112021020426A2 BR 112021020426 A2 BR112021020426 A2 BR 112021020426A2 BR 112021020426 A BR112021020426 A BR 112021020426A BR 112021020426 A BR112021020426 A BR 112021020426A BR 112021020426 A2 BR112021020426 A2 BR 112021020426A2
Authority
BR
Brazil
Prior art keywords
methods
antibodies
generation
dependent anti
engineered
Prior art date
Application number
BR112021020426A
Other languages
English (en)
Inventor
Bianka Prinz
James Geoghegan
Robert Pejchal
Original Assignee
Adimab Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adimab Llc filed Critical Adimab Llc
Publication of BR112021020426A2 publication Critical patent/BR112021020426A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

anticorpos anti-cd3 dependentes de ph projetados e métodos para sua geração e uso. a presente invenção refere-se a domínios de ligação anti-cd3 dependentes de ph projetados e anticorpos e/ou domínios de ligação a antígeno compreendendo os mesmos, incluindo anticorpos multi-específicos, com, inter alia, ativação desejável de células t e potência e capacidade de desenvolvimento de células alvo (re)direcionadas, perfis são fornecidos, bem como métodos para sua identificação, isolamento e geração, e métodos para sua preparação e uso.
BR112021020426A 2019-06-07 2020-06-08 Anticorpos anti-cd3 dependentes de ph projetados e métodos para sua geração e uso BR112021020426A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962858968P 2019-06-07 2019-06-07
PCT/US2020/036657 WO2020247932A1 (en) 2019-06-07 2020-06-08 Engineered ph-dependent anti-cd3 antibodies, and methods for their generation and use

Publications (1)

Publication Number Publication Date
BR112021020426A2 true BR112021020426A2 (pt) 2022-03-08

Family

ID=73652648

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021020426A BR112021020426A2 (pt) 2019-06-07 2020-06-08 Anticorpos anti-cd3 dependentes de ph projetados e métodos para sua geração e uso

Country Status (12)

Country Link
US (1) US20220380463A1 (pt)
EP (1) EP3980465A4 (pt)
JP (1) JP2022536246A (pt)
KR (1) KR20220035368A (pt)
CN (1) CN114144437A (pt)
AU (1) AU2020287384A1 (pt)
BR (1) BR112021020426A2 (pt)
CA (1) CA3141914A1 (pt)
IL (1) IL288620A (pt)
MX (1) MX2021014966A (pt)
SG (1) SG11202111330XA (pt)
WO (1) WO2020247932A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202002248TA (en) 2017-10-02 2020-04-29 Visterra Inc Antibody molecules to cd138 and uses thereof
EP4355785A1 (en) * 2021-06-17 2024-04-24 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
CA3226397A1 (en) 2021-07-22 2023-01-26 Ignacio Moraga GONZALEZ Therapeutic muteins
WO2023097254A1 (en) * 2021-11-24 2023-06-01 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof
CN117924510B (zh) * 2024-03-21 2024-06-04 北京星基贝勤生物科技有限公司 靶向egfr和axl的双特异性抗体及其药物偶联物与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0511782B8 (pt) * 2004-06-03 2021-05-25 Novimmune Sa anticorpos anti-cd3, uso e método de produção dos mesmos, composição farmacêutica, molécula de ácido nucleico isolada e vetor
TWI564021B (zh) * 2008-04-11 2017-01-01 Chugai Pharmaceutical Co Ltd Repeated binding of antigen to antigen binding molecules
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
EP4257613A3 (en) * 2016-06-14 2023-12-13 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
WO2018075974A2 (en) * 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
CN108264566B (zh) * 2016-12-30 2021-05-14 惠和生物技术(上海)有限公司 一种融合抗cd3抗体结构域和t细胞正共刺激分子配体的双特异性分子及其应用
WO2018208864A1 (en) * 2017-05-08 2018-11-15 Adimab, Llc Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use

Also Published As

Publication number Publication date
EP3980465A4 (en) 2023-11-01
US20220380463A1 (en) 2022-12-01
KR20220035368A (ko) 2022-03-22
AU2020287384A1 (en) 2021-11-11
EP3980465A1 (en) 2022-04-13
JP2022536246A (ja) 2022-08-15
WO2020247932A1 (en) 2020-12-10
CN114144437A (zh) 2022-03-04
IL288620A (en) 2022-02-01
MX2021014966A (es) 2022-04-11
SG11202111330XA (en) 2021-12-30
CA3141914A1 (en) 2020-12-10

Similar Documents

Publication Publication Date Title
BR112021020426A2 (pt) Anticorpos anti-cd3 dependentes de ph projetados e métodos para sua geração e uso
MX2019013184A (es) Dominios de union a anti-cd3 y anticuerpos que los comprenden, y metodos para su generacion y uso.
CO2021003724A2 (es) Proteínas de fijación a sirpα y métodos de uso de estas
UY38049A (es) Anti-pd-1 anticuerpos y métodos de tratamiento
AU2018258045A1 (en) Chimeric antibody/T-cell receptor constructs and uses thereof
PE20191812A1 (es) Compuestos y metodos para la reduccion celular especifica de tumor
BR112018002844A2 (pt) receptores de antígeno quimérico à base de anticorpos de domínio único e métodos de uso dos mesmos
AR103488A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
BRPI0821777B8 (pt) anticorpo biespecífico bivalente, método para a preparação do mesmo e composição
CL2023000895A1 (es) Receptores quiméricos de dll3 y métodos para su uso
PE20151613A1 (es) Construcciones de anticuerpos para cdh19 y cd3
BR112012004823A8 (pt) Anticorpo ou fragmento de ligação de antígeno do mesmo, uso de um anticorpo ou um fragmento de ligação de antígeno do mesmo, e composição farmacêutica
CO6280541A2 (es) Anticuerpos monoclonales o fragmentos del mismo que se unen al recptor humano ox40
AR080873A1 (es) Anticuerpos contra factor de crecimiento epidermico (anti-erbb3 o anti-her3)
BR112013003361B8 (pt) Anticorpo, composição, conjugado de anticorpo,formulação farmacêutica e uso do anticorpo
BR112015025306A2 (pt) anticorpo biespecífico, anticorpos, composição farmacêutica, uso do anticorpo biespecífico, sequência de ácido nucleico, vetor de expressão, célula hospedeira procariótica ou eucariótica e método de produção de um anticorpo
BR112019008063A2 (pt) anticorpos contra o vírus sincicial anti-respiratório e métodos de sua geração e uso
CR20120312A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
BR112015023262B8 (pt) Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo
MX2020009116A (es) Proteinas triespecificas de union a antigenos.
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
BR112022011790A2 (pt) Agentes de ligação a ilt3 e métodos de uso dos mesmos
EA201590459A1 (ru) Специфические антитела к островковому амилоидному полипептиду человека (hiapp) и их применение
BR112018014355A2 (pt) processos para a preparação de f-benzoxazinorifamicina i e para a preparação de 2-amino-5-fluorobenzeno-1,3-diol iii
EA201400447A1 (ru) АНТИТЕЛА К CD1d